Compare Stocks: LGVN, EDSA, BYSI, and QNCX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BYSI BeyondSpring	$0.76 -3.7%	$0.79	$0.57 ▼ $2.44	$31.13M	-0.21	302,193 shs	73,903 shs
EDSA Edesa Biotech	$3.86 -1.4%	$4.67	$0.72 ▼ $20.32	$37.37M	1.2	1.59 million shs	3,514 shs
LGVN Longeveron	$2.39 -5.0%	$5.98	$2.30 ▼ $12.30	$7.61M	-0.19	222,386 shs	48,297 shs
QNCX Quince Therapeutics	$27.67 -1.5%	$30.03	$15.10 ▼ $909.98	$28.22M	1.33	196,470 shs	18,544 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BYSI BeyondSpring	-0.17%	-29.82%	+27.16%	-52.65%	-55.09%
EDSA Edesa Biotech	+1.30%	+7.12%	-17.34%	-46.44%	+52.73%
LGVN Longeveron	-2.71%	-4.56%	-63.14%	-60.30%	-68.16%
QNCX Quince Therapeutics	-3.77%	-3.10%	-10.28%	+60.57%	-91.48%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BYSI BeyondSpring	$0.76 -3.7%	$0.79	$0.57 ▼ $2.44	$31.13M	-0.21	302,193 shs	73,903 shs
EDSA Edesa Biotech	$3.86 -1.4%	$4.67	$0.72 ▼ $20.32	$37.37M	1.2	1.59 million shs	3,514 shs
LGVN Longeveron	$2.39 -5.0%	$5.98	$2.30 ▼ $12.30	$7.61M	-0.19	222,386 shs	48,297 shs
QNCX Quince Therapeutics	$27.67 -1.5%	$30.03	$15.10 ▼ $909.98	$28.22M	1.33	196,470 shs	18,544 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BYSI BeyondSpring	-0.17%	-29.82%	+27.16%	-52.65%	-55.09%
EDSA Edesa Biotech	+1.30%	+7.12%	-17.34%	-46.44%	+52.73%
LGVN Longeveron	-2.71%	-4.56%	-63.14%	-60.30%	-68.16%
QNCX Quince Therapeutics	-3.77%	-3.10%	-10.28%	+60.57%	-91.48%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BYSI BeyondSpring	1.00	Sell	N/A	N/A
EDSA Edesa Biotech	2.67	Moderate Buy	$5.00	29.63% Upside
LGVN Longeveron	2.00	Hold	$80.00	3,254.30% Upside
QNCX Quince Therapeutics	2.62	Moderate Buy	$206.71	647.07% Upside

Current Analyst Ratings Breakdown

Latest LGVN, EDSA, BYSI, and QNCX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/1/2026	QNCX Quince Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
9/29/2026	QNCX Quince Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/29/2026	QNCX Quince Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
9/24/2026	QNCX Quince Therapeutics	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$70.00
9/24/2026	QNCX Quince Therapeutics	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$70.00
9/22/2026	QNCX Quince Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
9/22/2026	QNCX Quince Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$77.00
9/21/2026	EDSA Edesa Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/8/2026	LGVN Longeveron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/3/2026	BYSI BeyondSpring	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/27/2026	QNCX Quince Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 10/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BYSI BeyondSpring	N/A	N/A	$0.11 per share	6.93	($0.59) per share	N/A
EDSA Edesa Biotech	N/A	N/A	N/A	N/A	$0.45 per share	N/A
LGVN Longeveron	$1.20M	6.34	N/A	N/A	$2.47 per share	0.97
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	($128.18) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BYSI BeyondSpring	-$1.01M	-$0.12	N/A	N/A	N/A	N/A	N/A	-28.88%	11/12/2026 (Estimated)
EDSA Edesa Biotech	-$7.19M	-$1.69	N/A	N/A	N/A	N/A	-560.22%	-105.74%	12/11/2026 (Estimated)
LGVN Longeveron	-$22.70M	-$9.90	N/A	N/A	N/A	-1,977.59%	-223.19%	-150.20%	11/3/2026 (Estimated)
QNCX Quince Therapeutics	-$83.98M	-$156.71	N/A	N/A	N/A	N/A	N/A	-133.84%	11/11/2026 (Estimated)

Latest LGVN, EDSA, BYSI, and QNCX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/3/2026	Q3 2026	LGVN Longeveron	-$1.95	N/A	N/A	N/A	$0.56 million	N/A
8/14/2026	Q2 2026	BYSI BeyondSpring	-$0.54	-$0.02	+$0.52	-$0.02	$8.77 million	N/A
8/14/2026	Q2 2026	QNCX Quince Therapeutics	-$28.02	-$12.31	+$15.71	-$12.31	N/A	N/A
8/13/2026	Q3 2026	EDSA Edesa Biotech	-$0.4350	-$0.60	-$0.1650	-$0.60	N/A	N/A
8/12/2026	Q2 2026	LGVN Longeveron	-$1.75	-$0.19	+$1.56	-$1.90	$0.33 million	$0.29 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A
EDSA Edesa Biotech	N/A	N/A	N/A	N/A	N/A
LGVN Longeveron	N/A	N/A	N/A	N/A	N/A
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BYSI BeyondSpring	N/A	0.70	0.70
EDSA Edesa Biotech	N/A	2.76	2.76
LGVN Longeveron	N/A	2.63	2.63
QNCX Quince Therapeutics	N/A	14.52	14.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BYSI BeyondSpring	40.29%
EDSA Edesa Biotech	5.50%
LGVN Longeveron	10.01%
QNCX Quince Therapeutics	30.75%

Insider Ownership

Company	Insider Ownership
BYSI BeyondSpring	29.31%
EDSA Edesa Biotech	24.40%
LGVN Longeveron	7.42%
QNCX Quince Therapeutics	5.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BYSI BeyondSpring	44	41.12 million	29.07 million	Optionable
EDSA Edesa Biotech	17	9.64 million	7.29 million	Not Optionable
LGVN Longeveron	38	3.19 million	2.95 million	Not Optionable
QNCX Quince Therapeutics	38	1.02 million	960,000	Optionable

LGVN, EDSA, BYSI, and QNCX Headlines

Recent News About These Companies

Zacks Research Upgrades Quince Therapeutics (NASDAQ:QNCX) to Hold

October 3 at 6:03 AM | americanbankingnews.com

Quince Therapeutics Maps LAM-001 Trials, With BOS Data Due in 2027

October 2, 2026 | americanbankingnews.com

Leerink Partners Reaffirms Their Buy Rating on Quince Therapeutics (QNCX)

October 1, 2026 | theglobeandmail.com

Quince Therapeutics, Inc. (QNCX) Discusses LAM-001 Clinical Progress in Pulmonary Hypertension and Bronchiolitis Obliterans Syndrome Transcript

September 28, 2026 | seekingalpha.com

Quince Therapeutics (NASDAQ:QNCX) Research Coverage Started at Rodman & Renshaw

September 27, 2026 | americanbankingnews.com

Rodman & Renshaw initiates coverage of Quince Therapeutics with a buy

September 24, 2026 | msn.com

Quince Therapeutics stock falls 3.83 percent on Nasdaq

September 24, 2026 | ad-hoc-news.deA

Quince Therapeutics stock prepares for LAM-001 KOL event as shares trade below recent highs

September 19, 2026 | ad-hoc-news.deA

Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on ...

September 17, 2026 | finance.yahoo.com

Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026

September 17, 2026 | globenewswire.com

Quince Therapeutics to Participate in September 2026 Investor Conferences

September 3, 2026 | quiverquant.comQ

Quince Therapeutics to Participate in September 2026 Investor Conferences

September 3, 2026 | globenewswire.com

Quince Therapeutics Announces Planned Presidential Leadership Transition

August 27, 2026 | tipranks.com

Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update

August 14, 2026 | globenewswire.com

Quince Therapeutics

July 6, 2026 | fool.com

Quince Therapeutics Stock Short Interest Report | NASDAQ:QNCX | Benzinga

July 2, 2026 | benzinga.com

Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board

June 30, 2026 | globenewswire.com

Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript

June 11, 2026 | seekingalpha.com

Quince Therapeutics Inc. (QNCX) Presents Positive Phase 2a Data for LAM-001 Inhaled Therapy

June 2, 2026 | insidermonkey.com

Quince Therapeutics Regains Nasdaq Compliance, Avoids Delisting Risk

May 24, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGVN, EDSA, BYSI, and QNCX Company Descriptions

BeyondSpring NASDAQ:BYSI

$0.76 -0.03 (-3.69%)

As of 01:04 PM Eastern

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Edesa Biotech NASDAQ:EDSA

$3.86 -0.05 (-1.36%)

As of 01:11 PM Eastern

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

Longeveron NASDAQ:LGVN

$2.38 -0.13 (-4.98%)

As of 01:07 PM Eastern

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

Quince Therapeutics NASDAQ:QNCX

$27.67 -0.43 (-1.53%)

As of 01:06 PM Eastern

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LGVN, EDSA, BYSI, and QNCX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LGVN, EDSA, BYSI, and QNCX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LGVN, EDSA, BYSI, and QNCX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGVN, EDSA, BYSI, and QNCX Company Descriptions

BeyondSpring NASDAQ:BYSI

Edesa Biotech NASDAQ:EDSA

Longeveron NASDAQ:LGVN

Quince Therapeutics NASDAQ:QNCX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LGVN, EDSA, BYSI, and QNCX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LGVN, EDSA, BYSI, and QNCX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LGVN, EDSA, BYSI, and QNCX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGVN, EDSA, BYSI, and QNCX Company Descriptions

BeyondSpring NASDAQ:BYSI

Edesa Biotech NASDAQ:EDSA

Longeveron NASDAQ:LGVN

Quince Therapeutics NASDAQ:QNCX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools